ABI-007
information and resources from the National Cancer Institute
ABI-007
A Cremophor ELP-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of Cremophor ELP and permits the administration of larger doses of this agent, which would be toxic in a Cremophor ELP-containing formulation due to Cremophor ELP's toxicity profile. Cremophor ELP is a nonionic solubilizer made by reacting castor oil with ethylene oxide in a molar ratio of 1:35, followed by a purification step. ABI-007
A Cremophor ELP-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of Cremophor ELP and permits the administration of larger doses of this agent, which would be toxic in a Cremophor ELP-containing formulation due to Cremophor ELP's toxicity profile. Cremophor ELP is a nonionic solubilizer made by reacting castor oil with ethylene oxide in a molar ratio of 1:35, followed by a purification step.
|
|
|
|
news articles
Abraxane™ Safe When Used in Dose-Dense Therapy Regimen for ... Dec 19, 2005
Cancer Consultants (press release), Researchers affiliated with the US Oncology Research Network recently reported that the addition of dose-dense Abraxane (ABI-007) in the dose-dense AC ...
Pilot Study Shows Abraxane Safe and Effective in Sequence with ... Dec 13, 2005
DG News Each molecule of Abraxane (ABI-007) measures 130 nm in diameter, which permits it to cross blood vessel membranes, pass through the interstitium (the area ...
Positive ABRAXANE(R) Data in Early-Stage (Adjuvant) Breast Cancer ... Dec 9, 2005
PR Newswire (press release), Pilot Study of Dose-Dense Doxorubicin plus Cyclophosphamide Followed by ABI-007 (ABRAXANE) in Patients with Early-Stage Breast Cancer Nicholas Robert, MD, US ...
Abraxane™ Safe When Used in Dose-Dense Therapy Regimen for ... Dec 19, 2005
Cancer Consultants (press release), Researchers affiliated with the US Oncology Research Network recently reported that the addition of dose-dense Abraxane (ABI-007) in the dose-dense AC ...
Pilot Study Shows Abraxane Safe and Effective in Sequence with ... Dec 13, 2005
DG News Each molecule of Abraxane (ABI-007) measures 130 nm in diameter, which permits it to cross blood vessel membranes, pass through the interstitium (the area ...
Positive ABRAXANE(R) Data in Early-Stage (Adjuvant) Breast Cancer ... Dec 9, 2005
PR Newswire (press release), Pilot Study of Dose-Dense Doxorubicin plus Cyclophosphamide Followed by ABI-007 (ABRAXANE) in Patients with Early-Stage Breast Cancer Nicholas Robert, MD, US ...
|
|
